These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2008-001340-39||Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial.||not-yet-due|
|Listed as ongoing, but also has a completion date||2011-002749-37||Validation of digital-PCR analysis through programmed imatinib interruption in PCR negative chronic myeloid leukemia patients.||2018-11-28||bad-data|
|Completed, but no date, and reported results||2014-003126-40||Allogeneic haematopoietic stem cell transplantation from a matched donor in patients with chronic myeloid leukemia failing to gain normal hemopoiesis under TKIs therapy||bad-data|
|Ongoing||2016-003970-41||A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS STUDIO DI FASE 2 IN APERTO CON LORLATINIB (PF-0646...||not-yet-due|
|Other||2017-000705-20||International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones||not-yet-due|
|Ongoing||2019-000510-11||A Phase 2, open label, multicenter, single arm trial evaluating the activity and safety of Abemaciclib + Aromatase Inhibitors (AIs) after 1st-line treatment with High-Dose Fulvestrant in Hormone-Recep...||not-yet-due|